Put It on the Board

Create PDF

Illumina says the initial focus of the collaboration will be the co-development of multiple companion diagnostic claims in blood cancers for Kartos’ KRT-232, an oral MDM2 inhibitor that activates p53 to drive tumor cell death in TP53 wild-type cancers.

Philips, Ibex team up for AI-powered digital pathology

Royal Philips and artificial intelligence company Ibex Medical Analytics announced a collaboration to promote their digital pathology and AI solutions to hospitals, health networks, and pathology labs worldwide.

Ibex’s Galen AI-powered cancer diagnostics platform is currently in clinical use in Europe and the Middle East. Ibex uses AI to develop clinical-grade solutions that help pathologists detect and grade cancer in biopsies. The companies say the combination of Philips’ digital pathology solutions and Ibex’s Galen platform has improved reporting efficiency, productivity, and accuracy.

Hologic to buy Mobidiag

Hologic has signed a definitive agreement to acquire Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, for an enterprise value of about $795 million.

“Acquiring Mobidiag will further strengthen our international and diagnostics businesses by enabling us to expand into the large, fast-growing acute care adjacency with a near-patient testing solution that offers ease of use, multiplex capability, and rapid turnaround time,” Jan Verstreken, Hologic group president, international, said in an April 8 statement.

Mobidiag develops and markets PCR-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and health-care–associated infections. The Amplidiag and Novodiag platforms are automated instruments with turnaround times ranging from 50 minutes to two hours.

The acquisition is expected to close early in the fourth quarter of fiscal 2021.

DiaSorin to buy Luminex

DiaSorin SpA has agreed to acquire Luminex for about $1.8 billion.

DiaSorin will gain access to Luminex’s molecular diagnostics multiplexing technology and a portfolio that will strengthen its existing offering while expanding its presence in the United States. The transaction is expected to close in the third quarter of this year.

Latest on COVID-19

Editor’s note: See captodayonline.com for news on SARS-CoV-2 tests (Coronavirus News). A list of FDA EUAs for COVID-19 can be found at https://j.mp/covid-19-EUA.